A Randomized, Placebo-Controlled, Double-Blinded Phase I Safety and Immunogenicity Trial of Recombinant Envelope Protein, HIV-1 SF-2 rgp120 (BIOCINE), Combined With MF59 in HIV-1 Uninfected Adult Volunteers

计划入组 30 人 · 首次发布于 2001 年 8 月 31 日

A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of 200 Mcg of gp120 (CHO) BIOCINE in MF59 Emulsion Versus the Emulsion Control: Three Injections at 0, 1, and 6 Months

计划入组 14 人 · 首次发布于 2001 年 8 月 31 日

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Compare the Safety and Immunogenicity of Recombinant Envelope Protein rgp120/HIV-1SF2 (BIOCINE) Combined With Seven Adjuvants in Healthy HIV-1 Uninfected Individuals

计划入组 112 人 · 首次发布于 2001 年 8 月 31 日

Biotin(Concept Ob, Infuvite, Infuvite Pediatric, Irospan 24/6 Kit, Mvi Pediatric)

C₁₀H₁₆N₂O₃S

R-biolin

Niacin(Advicor, Concept Ob, Irospan 24/6 Kit, Mvc-fluoride, Niacor, Niaspan, Niodan, Simcor, Vitafol-one, Tredaptive)

C₆H₅NO₂

Biocon Ltd.

India

BIOCON LIMITED

India

Biocon SA

Switzerland

ImmuPharma Advances P140 Autoimmune Program with Novel Non-Immunosuppressive Mechanism

BioCina Partners with EnGeneIC to Manufacture Novel Nanocell Cancer Therapy

Patrys Initiates Manufacturing and FDA Engagement for Injectable Delirium Treatment RLS-2201